IN8bio, Inc.
NASDAQ:INAB
0.2301 (USD) • At close October 17, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 2.501 | 1.103 | 0.251 | 0.096 | 0.096 | 0.096 |
| Gross Profit
| -2.501 | -1.103 | -0.251 | -0.096 | -0.096 | -0.096 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 16.827 | 14.062 | 7.347 | 5.378 | 2.358 | 0.581 |
| General & Administrative Expenses
| 13.51 | 14.459 | 7.306 | 3.179 | 2.708 | 1.423 |
| Selling & Marketing Expenses
| -2.501 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 13.51 | 14.459 | 7.306 | 3.179 | 2.708 | 1.423 |
| Other Expenses
| 16.827 | 0 | 0 | 0 | 0 | -0.063 |
| Operating Expenses
| 30.337 | 28.521 | 14.653 | 8.557 | 5.066 | 2.004 |
| Operating Income
| -30.337 | -28.521 | -14.653 | -8.557 | -5.134 | -2.004 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.33 | 0 | 0 | 0 | -0.068 | -0.063 |
| Income Before Tax
| -30.007 | -28.521 | -14.653 | -8.557 | -5.134 | -2.081 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -32.838 | -1.103 | 0.551 | -0.118 | -0.068 | -0.063 |
| Net Income
| -30.007 | -27.418 | -14.653 | -8.557 | -5.134 | -2.081 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| EPS Diluted
| -1 | -1.31 | -0.78 | -0.44 | -0.27 | -0.34 |
| EBITDA
| -28.504 | -28.521 | -13.865 | -8.469 | -4.97 | -1.971 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 |